麝香保心丸联合托拉塞米治疗慢性充血性心力衰竭疗效观察及对血管内皮功能的影响
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.6+1

基金项目:


Observation on Curative Effect of Shexiang Baoxin Pills Combined with Torasemide on Chronic Congestive Heart Failure and Its Effects on Vascular Endothelial Function
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察麝香保心丸联合托拉塞米治疗慢性充血性心力衰竭(CHF) 的疗效及其对血管内皮功 能的影响。方法:对103 例CHF 患者进行回顾性分析,根据不同治疗方法分为对照组51 例和治疗组52 例。 对照组给予静脉注射托拉塞米注射液治疗,治疗组在对照组基础上加用麝香保心丸治疗。比较2 组治疗前后主 要症状评分、心功能指标[左室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)]、血管内皮功能指 标[内皮素(ET)、一氧化氮(NO)、肱动脉血管舒张功能(FMD)]、B 型脑钠肽(BNP) 水平变化,并分析 其临床疗效及不良反应发生率。结果:治疗组总有效率为94.23%,对照组为80.39%,2 组比较,差异有统计 学意义(P<0.05)。治疗前,2 组心悸、气短、疲倦乏力、面浮肢肿、胸闷(痛) 评分比较,差异无统计学意 义(P>0.05);治疗后,2 组各上述各项症状评分均较治疗前降低(P<0.05),且治疗组各项评分均低于对照 组(P<0.05)。治疗前,2 组LVEF、SV、CI 水平比较,差异无统计学意义(P>0.05);治疗后,2 组上述各 心功能指标均较治疗前升高(P<0.05),且治疗组各项指标均高于对照组(P<0.05)。治疗前,2 组ET、 NO、FMD、BNP 水平比较,差异无统计学意义(P>0.05)。治疗后,2 组ET、BNP 水平均较治疗前降 低(P<0.05),NO、FMD 水平均较治疗前升高(P<0.05);且治疗组上述各项指标改善较对照组更显著(P< 0.05)。治疗期间,治疗组不良反应发生率为7.69%,对照组为9.80%,2 组比较,差异无统计学意义(P> 0.05)。结论:麝香保心丸联合托拉塞米治疗CHF 临床疗效显著,能有效改善患者心力衰竭症状、心功能和血 管内皮功能,降低BNP 水平,且安全性良好。

    Abstract:

    Abstract: Objective: To observe the curative effect of Shexiang Baoxin Pills combined with Torasemide on chronic congestive heart failure (CHF) and its effects on vascular endothelial function. Methods: A total of 103 patients with CHF were given retrospective analysis and divided into the control group and the treatment group according to different treatment methods, with 51 and 52 cases in each group. The control group was treated with the intravenous injection of Torasemide, and the treatment group was additionally given Shexiang Baoxin Pills based on the treatment of the control group. Before and after treatment, the changes of scores of main symptoms, indexes of heart function, including left ventricular ejection fraction (LVEF), stroke volume (SV) and cardiac index (CI), indexes of vascular endothelial function, including endothelin (ET), nitric oxide (NO) and brachial artery flow- mediated dilatation (FMD) as well as levels of B- type natriuretic peptide (BNP) were compared between the two groups. The clinical effects and incidence of adverse reactions in both groups were also analyzed. Results: The total effective rate was 94.23% in the treatment group, and 80.39% in the control group, the difference being significant(P<0.05). Before treatment,there was no significant difference being found in the comparisons of scores of palpitation,shortness of breath,fatigue and lack of strength,facial edema and bloated limbs, and chest distress (pain) between the two groups (P>0.05); after treatment, the above five scores in both groups were decreased when compared with those before treatment (P<0.05), and the above five scores in the treatment group were lower than those in the control group (P<0.05). Before treatment, there was no significant difference being found in the comparisons of levels of LVEF, SV and CI between the two groups (P>0.05);after treatment,the above three levels of indexes of heart function in the two groups were increased when compared with those before treatment (P<0.05),and the above three levels in the treatment group were higher than those in the control group (P<0.05). Before treatment,there was no significant difference being found in the comparisons of levels of ET,NO,FMD and BNP between the two groups (P>0.05). After treatment,the levels of ET and BMP in the two groups were decreased when compared with those before treatment (P<0.05), and the levels of NO and FMD were increased when compared with those before treatment (P<0.05); the improvement in above four indexes in the treatment group was more significant than that in the control group (P<0.05). During treatment,the incidence of adverse reactions was 7.69% in the treatment group,and 9.80% in the control group, there being no significance in the difference between the two groups (P>0.05). Conclusion: Shexiang Baoxin Pills combined with Torasemide has a significant clinical effect on patients with CHF, which can effectively improve the symptoms of heart failure,the heart function and the vascular endothelial function of patients,and reduce the BNP level,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

张娜.麝香保心丸联合托拉塞米治疗慢性充血性心力衰竭疗效观察及对血管内皮功能的影响[J].新中医,2023,55(8):38-42

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-04-25
  • 出版日期:
文章二维码